ArticleAntimicrobial agents and chemotherapy2017
Nanotized Curcumin and Miltefosine, a Potential Combination for Treatment of Experimental Visceral Leishmaniasis.
Article in Antimicrobial agents and chemotherapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 76 citations in OpenAlex.
- Curcumin ((1E,6E)-1,7-bis(4-Hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) Induces Apoptosis-like Death inPathogens (Basel, Switzerland) · 2026Article
- In Vitro Assessment of the Combined Activity of Amphotericin B and CuTropical medicine and infectious disease · 2025Article
- β-Cyclodextrin Inclusion Complexes of Curcumin and Synthetic Analogues in PVA/Carrageenan Hydrogels: A Platform for Sustained Release and Microbial Control.Gels (Basel, Switzerland) · 2025Article
- In Vitro and In Silico Assessments of Curcuminoids and Turmerones fromPharmaceuticals (Basel, Switzerland) · 2025Article
- Combinatorial Treatment with Praziquantel and Curcumin ReducesPharmaceutics · 2024Article
- In vitro and in vivo anti-parasitic activity of curcumin nanoemulsion on Leishmania major (MRHO/IR/75/ER).BMC complementary medicine and therapies · 2024Article
- The influence of plant extracts on viability of ST3 and ST7 subtypes of Blastocystis sp.Gut pathogens · 2024Article
- The Prospects of Phytomedicines and Nanomedicines to Treat Leishmaniasis: A Comprehensive Review.Current drug research reviews · 2024Review
- Curcumin-loaded nanostructured systems for treatment of leishmaniasis: a review.Beilstein journal of nanotechnology · 2024Review
- Neglected Zoonotic Diseases: Advances in the Development of Cell-Penetrating and Antimicrobial Peptides against Leishmaniosis and Chagas Disease.Pathogens (Basel, Switzerland) · 2023Review
- The Therapeutic Effects of Curcumin-coated Gold Nanoparticle Against Leishmania Major Causative Agent of Zoonotic Cutaneous Leishmaniasis (ZCL): An In Vitro and In Vivo Study.Current microbiology · 2023Article
- A new immunochemotherapy schedule for visceral leishmaniasis in a hamster model.Parasitology research · 2022Article
- Curcumin: Biological Activities and Modern Pharmaceutical Forms.Antibiotics (Basel, Switzerland) · 2022Review
- Nano- and Microformulations to Advance Therapies for Visceral Leishmaniasis.ACS biomaterials science & engineering · 2021Review
- Nanotechnology based solutions for anti-leishmanial impediments: a detailed insight.Journal of nanobiotechnology · 2021Review
- Effects of Curcumin and Its Analogues on Infectious Diseases.Advances in experimental medicine and biology · 2021Review
- An Overview on the Therapeutics of Neglected Infectious Diseases-Leishmaniasis and Chagas Diseases.Frontiers in chemistry · 2021Review
- Gold-Silver Bimetallic Nanoparticles Reduced with Herbal Leaf Extracts Induce ROS-Mediated Death in Both Promastigote and Amastigote Stages ofACS omega · 2020Article
- Novel chloroquine loaded curcumin based anionic linear globular dendrimer G2: a metabolomics study onParasitology · 2020Article
- Envisioning the innovations in nanomedicine to combat visceral leishmaniasis: for future theranostic application.Nanomedicine (London, England) · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leishmaniasis chemotherapy remains very challenging due to high cost of the drug and its associated toxicity and drug resistance, which develops over a period of time. Combination therapies (CT) are now in use to treat many diseases, such as cancer and malaria, since it is more effective and affordable than monotherapy. CT are believed to represent a new explorable strategy for leishmaniasis, a neglected tropical disease caused by the obligate intracellular parasite
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.